Josephine Harrington

May 16, 2024 | onlinelibrary.wiley.com | Anthony Peters |Robert M. Clare |Karen Chiswell |Josephine Harrington

Introduction Heart failure (HF) with preserved ejection fraction (HFpEF) represents a highly prevalent public health burden, affecting more than 50% of the 6 million patients in the United States with HF.1, 2 Outcomes for patients with HFpEF remain poor with high rates of hospitalization and death along with low quality of life.1-3 Improvements in outcomes are lagging due to limited effective therapies.

May 11, 2024 | onlinelibrary.wiley.com | Stephen Greene |Joseph B. Lerman |Josephine Harrington |RaKavius Chambers

Supporting Information Filename Description ejhf3199-sup-0001-Tables.docxWord 2007 document , 34.9 KB Appendix S1. Supporting Information. References 1, . Coronavirus disease 2019 (COVID-19) and the heart – Is heart failure the next chapter? JAMA Cardiol 2020; 5: 1216–1217. https://doi.org/10.1001/jamacardio.2020.3575 2, , , , , , et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19).

Jan 1, 2024 | jacc.org | Josephine Harrington |G. Michael Felker |Ildiko Lingvay |Neha J. Pagidipati

References1. "Twenty years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study". Circulation . 2023;147:1872-1886. 2. "Obesity and cardiovascular disease: a scientific statement from the American Heart Association". Circulation . 2021;143:e984-e1010. 3. "Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction". Circulation . 2017;136:6-19. 4.

Aug 25, 2023 | onlinelibrary.wiley.com | Josephine Harrington |Jacob A. Udell |W. Schuyler Jones |Stefan Anker

Introduction Despite improvements in therapies, patients with acute myocardial infarction (AMI) are at high risk for mortality and for developing heart failure (HF).1 This risk is particularly high for patients with reduced left ventricular ejection fraction (LVEF), acute signs and symptoms of congestion at the time of AMI, or with other risk factors such as advanced age, type 2 diabetes (T2D), or chronic kidney disease.

Aug 25, 2023 | onlinelibrary.wiley.com | Josephine Harrington |Jacob A. Udell |W. Schuyler Jones |Stefan Anker

Introduction Despite improvements in therapies, patients with acute myocardial infarction (AMI) are at high risk for mortality and for developing heart failure (HF).1 This risk is particularly high for patients with reduced left ventricular ejection fraction (LVEF), acute signs and symptoms of congestion at the time of AMI, or with other risk factors such as advanced age, type 2 diabetes (T2D), or chronic kidney disease.